NB-PP_1170x120

Chip Davis

Making the Rx markets more competitive again

Making the Rx markets more competitive again

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the

Generic drugs see low abandonment rate

Generic drugs see low abandonment rate

WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics

AAM: REMS abuse trips up new generics

AAM: REMS abuse trips up new generics

The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and

New name for Generic Pharmaceutical Association

New name for Generic Pharmaceutical Association

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly

Savings from generic drugs edge up

Savings from generic drugs edge up

WASHINGTON — Annual health care savings from generic prescription drugs rose nearly 10% last year to $227 billion, according to the Generic Pharmaceutical Association (GPhA). GPhA’s 2016 Generic Drug Savings and Access in the United States report, released Wednesday, tallied the 10-year national savings for generics at $1.46 trillion, representing a gain of 328% from

FDA pushes back generic drug labeling rule

FDA pushes back generic drug labeling rule

WASHINGTON — The Food and Drug Administration is again postponing the release of a final rule that would change generic drug labeling requirements. In a Federal Register notice this week, the FDA indicated that it aims to implement the final rule in April 2017, though many industry stakeholders had expected the agency to do so

GPhA tabs Mylan’s Bresch to chair board

GPhA tabs Mylan’s Bresch to chair board

ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,

GPhA tallies savings from generic drug use

GPhA tallies savings from generic drug use

WASHINGTON — The U.S. health care system saved a record $254 billion last year through the use of lower-cost generic drugs, the Generic Pharmaceutical Association (GPhA) reports. Over the past decade, covering 2005 to 2014, the savings yielded by the use of generics over their more expensive brand-name counterparts totals $1.68 trillion, according to the